Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 165

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 165
---
 States reached € 19,986 million, up 15.8% on a reported basis and 16.2% CER. The strong performance was driven by new launches including Beyfortus and ALTUVIIIO ( €1,068 million and € 617 million respectively), and by Dupixent (+ 17.2% CER at € 9,544 million) and Lantus. Sales growth was slightly dampened by lower sales of legacy medicines. In Europe , net sales advanced by 2.4% on a reported basis and 2.3% at CER in 2024 to € 9,027 million. The effects of Aubagio generics and a high comparative base for vaccines due to COVID-19 vaccine sales recorded in 2023 were more than offset by the strong performance of Dupixent and Beyfortus. In the Rest of the World region , net sales for 2024 increased by 2.8% on a reported basis and by 10.7% CER to € 12,068 million, due to exceptional performances from Dupixent ( +50.8% CER at € 1,910 million) and the launch of Beyfortus in two countries in the southern hemisphere. A.2.2. Other income statement items 1/ Other revenues Other revenues decreased by 15.7 % to € 3,205 million in 2024 (versus € 3,801 million in 2023 ), due largely to the absence in 2024 of COVID-19 sales, which represented €509 million in 2023. The Other revenues line item also includes VaxServe sales of non-Sanofi products, amounting to € 1,959 million (versus € 2,167 million in 2023). In addition, Other revenues included sales of Opella products in markets retained by Sanofi (€ 339 million); sales to entities within the Opella scope that are classified as held for sale (€ 163 million); royalties (€ 121 million); and other services/ manufacturing services (€ 623 million).

| 76 | SANOFIFORM 20-F2024 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

2/ Gross profit Gross profit for 2024 amounted to € 31,081 million compared with € 28,990 million in 2023 , an increase of 7.2 %. Gross margin (the ratio of